Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ).
Biocytogen Pharmaceuticals has secured a patent in Japan for its RenMab™ fully human antibody mouse platform, marking a significant milestone in its global intellectual property strategy. This achievement enhances the company’s competitive edge in the biotech industry, as the RenMice platform has already generated numerous licensing agreements and high-potential therapeutic candidates, underscoring its substantial commercial value and global recognition.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a company in the biotech and biopharmaceutical industry, focusing on the development of fully human antibody discovery platforms. Their primary products include the RenMice platform series, which is recognized for its ability to discover fully human antibodies and TCRs with low immunogenicity and high diversity. The company has established licensing agreements with major companies like Merck KGaA and Janssen/Johnson & Johnson.
Average Trading Volume: 320,203
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.16B
Find detailed analytics on 2315 stock on TipRanks’ Stock Analysis page.